New models, methods and modalities are shaping the next generation of CNS therapies, including a wave of cellular and gene therapies. Charles River is committed to help in changing the course of neuroscience research as integrated Drug Discovery, Preclinical and CDMO partners. From chemistry to in vitro biology to in vivo efficacy through to IND, our scientists supported 86% novel FDA approved drugs in 2021.